Mustang Bio’s brain cancer-targeting gene therapy granted FDA Orphan Drug designation

(By Andrea Park for Becker’s Hospital Review)

A new gene therapy developed for the treatment of malignant glioma, a rare and fast-growing brain cancer, received Orphan Drug status from the FDA this week, New York City-based biopharmaceutical company Mustang Bio and Columbus, Ohio-based Nationwide Children’s Hospital announced.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.